Skip to main content
SpringerLink
Log in
Book cover

Stem Cell Biology in Neoplasms of the Central Nervous System pp 139–166Cite as

Immunobiology and Immunotherapeutic Targeting of Glioma Stem Cells

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 853))

Abstract

For decades human brain tumors have confounded our efforts to effectively manage and treat patients. In adults, glioblastoma multiforme is the most common malignant brain tumor with a patient survival of just over 14 months. In children, brain tumors are the leading cause of solid tumor cancer death and gliomas account for one-fifth of all childhood cancers. Despite advances in conventional treatments such as surgical resection, radiotherapy, and systemic chemotherapy, the incidence and mortality rates for gliomas have essentially stayed the same. Furthermore, research efforts into novel therapeutics that initially appeared promising have yet to show a marked benefit. A shocking and somewhat disturbing view is that investigators and clinicians may have been targeting the wrong cells, resulting in the appearance of the removal or eradication of patient gliomas only to have brain cancer recurrence. Here we review research progress in immunotherapy as it pertains to glioma treatment and how it can and is being adapted to target glioma stem cells (GSCs) as a means of dealing with this potential paradigm.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Allegra A, Alonci A, Penna G, Innao V, Gerace D, Rotondo F, Musolino C. The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest. 2014;32(9):470–95. doi:10.3109/07357907.2014.958231.

    Article  PubMed  Google Scholar 

  2. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.

    Article  CAS  PubMed  Google Scholar 

  3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature. 2004;432:396–401.

    Article  CAS  PubMed  Google Scholar 

  4. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma-stem like cells give rise to tumor epithelium. Nature. 2010;468:829–35.

    Article  CAS  PubMed  Google Scholar 

  5. Cheng L, Huang Z, Zhou W, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013;153(1):139–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Lathia JD, et al. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule as a cancer stem cell maintenance factor. Cell Rep. 2014;6(1):117–29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Ignatova TN, Kukekov VG, Laywell ED, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39:193–206.

    Article  PubMed  Google Scholar 

  9. Xiangpeng Y, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23:9392–400.

    Article  CAS  Google Scholar 

  10. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391–403.

    Article  CAS  PubMed  Google Scholar 

  11. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008;122(4):761–8.

    Article  CAS  PubMed  Google Scholar 

  12. Joo KM, Kim SY, Song SY, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008;88(4):808–15.

    Article  CAS  PubMed  Google Scholar 

  13. Barcelos LS, Duplaa C, Krankel N, et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res. 2009;104(9):1095–102.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Jin Son M, Woolard K, Nam D-H, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4(5):440–52.

    Article  CAS  Google Scholar 

  15. Anido J, Saez-Borderias A, Gonzalez-Junca A, et al. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18:655–68.

    Article  CAS  PubMed  Google Scholar 

  16. Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep. 2010;10(4):259–66.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. DeVita VT, Hellstrom S, Rosenberg SA. Biologic therapy of cancer, vol. 2. Philadelphia: J. B. Lippincott Company; 1995.

    Google Scholar 

  18. Butler TP, Grantham FH, Gullino PM. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res. 1975;35(11 Pt 1):3084–8. PubMed: 1182701.

    CAS  PubMed  Google Scholar 

  19. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macro-molecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48(24 Pt 1):7022–32. PubMed: 3191477.

    CAS  PubMed  Google Scholar 

  20. Williams LE, Duda RB, Proffitt RT, Beatty BG, Beatty JD, Wong JY, Shively JE, Paxton RJ. Tumor uptake as a function of tumor mass: a mathematic model. J Nucl Med. 1988;29(1):103–9.

    CAS  PubMed  Google Scholar 

  21. Wikstrand CJ, Cokgor I, Sampson JH, et al. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 1999;18(4):451–64.

    Article  CAS  PubMed  Google Scholar 

  22. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol. 1999;11(5):541–7.

    Article  CAS  PubMed  Google Scholar 

  24. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 2008;47(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  25. Ohno M, Natsume A, Ichiro Iwami K, et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 2010;101(12):2518–24.

    Article  CAS  PubMed  Google Scholar 

  26. Eller JL, Longo SL, Hicklin DJ, et al. Activity of antiepidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. 2002;51(4):1005–14.

    PubMed  Google Scholar 

  27. Faillot T, et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery. 1996;39:478–83.

    CAS  PubMed  Google Scholar 

  28. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997;57(18):4130–40.

    CAS  PubMed  Google Scholar 

  29. Zalutsky MR, Boskovitz A, Kuan CT, et al. Radioimmuno targeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol. 2012;39(1):23–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Yang W, Barth RF, Wu G, et al. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res. 2005;11(1):341–50.

    CAS  PubMed  Google Scholar 

  31. Perera RM, Narita Y, Furnari FB, et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res. 2005;11(17):6390–9.

    Article  CAS  PubMed  Google Scholar 

  32. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12):4119–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19(56):6550–65.

    Article  CAS  PubMed  Google Scholar 

  34. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating Bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31(suppl;abstr 1).

    Google Scholar 

  35. Day ED, Lassiter S, Woodhall B, Mahaley JL, Mahaley MS. The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res. 1965;25(6):773–8.

    CAS  PubMed  Google Scholar 

  36. Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer. 2004;90(8):1469–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43(6):2796–805.

    CAS  PubMed  Google Scholar 

  38. Riva P, Arista A, Franceschi G, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 1995;55(23 Suppl):5952s–6.

    CAS  PubMed  Google Scholar 

  39. Rosenkranz AA, Vaidyanathan G, Pozzi OR, Lunin VG, Zalutsky MR, Sobolev AS. Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. Int J Radiat Oncol Biol Phys. 2008;72(1):193–200.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. DeVita Jr VT, Lawrence TS, Rosenberg SA, et al., editors. Cancer: principles & practice of oncology. 9th ed. Philadelphia, PA: LWW; 2011.

    Google Scholar 

  41. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 1996;56(24):5631–7.

    CAS  PubMed  Google Scholar 

  42. Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol. 2005;7(1):90–6.

    Article  PubMed Central  PubMed  Google Scholar 

  43. vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell mediated glioma rejection. J Exp Med. 2013;210:2803–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Hayes RL, Arbit E, Odaimi M, et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol. 2001;39(1–2):31–42.

    Article  CAS  PubMed  Google Scholar 

  45. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823–41.

    Article  CAS  PubMed  Google Scholar 

  46. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg. 1988;208:121–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41(11 Pt 1):4420–5.

    CAS  PubMed  Google Scholar 

  48. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg. 1986;64(1):114–7.

    Article  CAS  PubMed  Google Scholar 

  49. Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64(24):9160–6.

    Article  CAS  PubMed  Google Scholar 

  51. Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009;94(3):373–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  53. Steinman RM, Cohn ZAJ. J Exp Med. 1973;137:1142–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Badhiwala J, Decker WK, Berens ME, Bhardwaj RD. Clinical trials in cellular immunotherapy for brain/CNS tumors. Expert Rev Neurother. 2013;13(4):405–24.

    Article  CAS  PubMed  Google Scholar 

  55. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol. 2012;2012:425–76.

    Article  CAS  Google Scholar 

  56. Ali-Osman F. Brain tumors. In: Masters JRW, Palson B, editors. Human cell culture, vol. 2. New York, NY: Kluwer Academic Publishers; 1999. p. 167–84.

    Chapter  Google Scholar 

  57. Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol. 1999;11(2):125–37.

    Article  CAS  PubMed  Google Scholar 

  58. Decker WK, Xing D, Shpall EJ. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant. 2006;12(2):113–25.

    Article  PubMed  Google Scholar 

  59. Li Z, Lee JW, Mukherjee D, et al. Immunotherapy targeting glioma stem cells—insights and perspectives. Expert Opin Biol Ther. 2012;12(2):165–78.

    Article  CAS  PubMed  Google Scholar 

  60. Yamanaka R, Itoh K. Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opin Biol Ther. 2007;7:645–9.

    Article  CAS  PubMed  Google Scholar 

  61. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247–54.

    CAS  PubMed  Google Scholar 

  62. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res. 1999;5(5):985–90.

    CAS  PubMed  Google Scholar 

  63. Shimato S, Natsume A, Wakabayashi T, Tsujimura K, Nakahara N, Ishii J, Ito M, Akatsuka Y, Kuzushima K, Yoshida J. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen. J Neurosurg. 2008;109(1):117–22.

    Article  CAS  PubMed  Google Scholar 

  64. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product. Immunogenetics. 2000;51(2):99–107.

    Article  CAS  PubMed  Google Scholar 

  65. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 2008;116(1):79–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with{α}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Huang J, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol (Orlando, Fla). 2013;149(1):156–68.

    Article  CAS  Google Scholar 

  68. Ikegame A, et al. Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia. 2012;26(9):2124–34.

    Article  CAS  PubMed  Google Scholar 

  69. Schlaak M, et al. Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget. 2012;3(1):22–30.

    PubMed Central  PubMed  Google Scholar 

  70. Ueda R, et al. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer. 2010;126(4):919–29.

    CAS  PubMed  Google Scholar 

  71. Xu Q, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells (Dayton, Ohio). 2009;27(8):1734–40.

    Article  CAS  Google Scholar 

  72. Xiao ZY, et al. An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors. Cancer Biol Ther. 2011;11(11):974–80. Web. 21 Mar. 2014.

    Article  CAS  PubMed  Google Scholar 

  73. Pellegatta S, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 2006;66(21):10247–52.

    Article  CAS  PubMed  Google Scholar 

  74. Ning N, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72(7):1853–64. Web. 21 Mar. 2014.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Natsume A, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008;122(11):2542–53. Web. 21 Mar. 2014.

    Article  CAS  PubMed  Google Scholar 

  76. Odunsi K, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003;63(18):6076–83.

    CAS  PubMed  Google Scholar 

  77. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986;46(4 Pt 2):2101–4.

    CAS  PubMed  Google Scholar 

  78. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989;70(2):175–82.

    Article  CAS  PubMed  Google Scholar 

  79. Blancher A, Roubinet F, Grancher AS, et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw. 1993;4(5):331–41.

    CAS  PubMed  Google Scholar 

  80. Boiardi A, Silvani A, Ruffini PA, et al. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother. 1994;39(3):193–7.

    Article  CAS  PubMed  Google Scholar 

  81. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer. 1988;62(4):665–71.

    Article  CAS  PubMed  Google Scholar 

  82. Merchant RE, Merchant LH, Cook SH, McVicar DW, Young HF. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery. 1988;23(6):725–32.

    Article  CAS  PubMed  Google Scholar 

  83. Sankhla SK, Nadkarni JS, Bhagwati SN. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol. 1996;27(2):133–40.

    Article  CAS  PubMed  Google Scholar 

  84. Bielamowicz K, Khawja S, Ahmed N. Adoptive cell therapies for glioblastoma. Front Oncol. 2013;3:275.

    Article  PubMed Central  PubMed  Google Scholar 

  85. Yoshida S, Tanaka R, Takai N, Ono K. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 1988;48(17):5011–6.

    CAS  PubMed  Google Scholar 

  86. Okamoto Y, Shimizu K, Tamura K, et al. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir. 1988;94(1–2):47–52.

    Article  CAS  PubMed  Google Scholar 

  87. Dillman RO, Duma CM, Schiltz PM, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 2004;27(5):398–404.

    Article  PubMed  Google Scholar 

  88. Dillman RO, Duma CM, Ellis RA, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother. 2009;32(9):914–9.

    Article  PubMed  Google Scholar 

  89. Kitahara T, Watanabe O, Yamaura A, et al. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol. 1987;4(4):329–36.

    Article  CAS  PubMed  Google Scholar 

  90. Kruse CA, et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997;45(2):77–87.

    Article  CAS  PubMed  Google Scholar 

  91. Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res. 2003;9(9):3294–302.

    PubMed  Google Scholar 

  92. Tsurushima H, Liu SQ, Tuboi K, et al. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res. 1999;90(5):536–45.

    Article  CAS  PubMed  Google Scholar 

  93. Quattrocchi KB, Miller CH, Cush S, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol. 1999;45(2):141–57.

    Article  CAS  PubMed  Google Scholar 

  94. Holladay FP, Heitz-Turner T, Bayer WL, Wood GW. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/ IV astrocytoma. J Neurooncol. 1996;27(2):179–89.

    Article  CAS  PubMed  Google Scholar 

  95. Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg. 1998;89(1):42–51.

    Article  CAS  PubMed  Google Scholar 

  96. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000;6(6):2209–18.

    CAS  PubMed  Google Scholar 

  97. Sloan AE, Dansey R, Zamorano L, et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte–macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus. 2000;9(6):e9.

    Article  CAS  PubMed  Google Scholar 

  98. Wood GW, Holladay FP, Turner T, Wang YY, Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent Grade III/IV astrocytoma. J Neurooncol. 2000;48(2):113–20.

    Article  CAS  PubMed  Google Scholar 

  99. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother. 2008;57(3):425–39.

    Article  PubMed  Google Scholar 

  100. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008;10(1):10–8.

    Article  PubMed Central  PubMed  Google Scholar 

  101. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347–50.

    CAS  PubMed  Google Scholar 

  102. Dziurzynski K, Wei J, Qiao W, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011;17(14):4642–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  103. Ishikawa E, Tsuboi K, Yamamoto T, et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci. 2007;98(8):1226–33.

    Article  CAS  PubMed  Google Scholar 

  104. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol. 2001;53(1):39–46.

    Article  CAS  PubMed  Google Scholar 

  105. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol. 2004;22(21):4272–81.

    Article  PubMed  Google Scholar 

  106. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50(7):337–44.

    Article  CAS  PubMed  Google Scholar 

  107. Yu JS, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial t-cell infiltration. Cancer Res. 2001;61(3):842–7.

    CAS  PubMed  Google Scholar 

  108. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973–9.

    Article  CAS  PubMed  Google Scholar 

  109. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68(14):5955–64.

    Article  CAS  PubMed  Google Scholar 

  110. Fadul CE, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (Hagerstown, Md 1997). 2011;34(4):382–9.

    Article  CAS  Google Scholar 

  111. Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys. 2012;62(1):91–9.

    Article  CAS  PubMed  Google Scholar 

  112. Cho DY, Yang WK, Lee HC, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a Phase II clinical trial. World Neurosurg. 2012;77(5–6):736–44.

    Article  PubMed  Google Scholar 

  113. Westphal M, Ferdinand B. Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temoziolamide. J Clin Oncol. 2012;30(Suppl):abstr 2033. Web. 28 July 2014.

    Google Scholar 

  114. Wen PY, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. J Clin Oncol. 2014;32(5s Suppl):abstr 2005. Web. 28 July 2014.

    Google Scholar 

  115. Yajima N, Yamanaka R, Mine T, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res. 2005;11(16):5900–11.

    Article  CAS  PubMed  Google Scholar 

  116. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108(5):963–71.

    Article  CAS  PubMed  Google Scholar 

  117. Morita S, Oka Y, Tsuboi A, et al. A Phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the Phase I data. Jpn J Clin Oncol. 2006;36(4):231–6.

    Article  PubMed  Google Scholar 

  118. Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  119. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722–9.

    Article  PubMed Central  PubMed  Google Scholar 

  120. Crane CA, Han SJ, Ahn B, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013;19(1):205–14.

    Article  CAS  PubMed  Google Scholar 

  121. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013;62(9):1499–509.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  122. Bigner DD, Brown M, Coleman RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14F(ab′)2—a preliminary report. J Neurooncol. 1995;24(1):109–22.

    Article  CAS  PubMed  Google Scholar 

  123. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia. 1995;15(3):244–56.

    Article  CAS  PubMed  Google Scholar 

  124. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol. 1991;115(4):1127–36.

    Article  CAS  PubMed  Google Scholar 

  125. Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20(9):1596–603.

    Article  CAS  PubMed  Google Scholar 

  126. Gil-gil JM, et al. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol. 2013;7:123–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  127. de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J. 2008;14(5):279–85.

    Article  PubMed  Google Scholar 

  128. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  129. Gilbert MR, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd, Los Angeles, CA, 90048, USA

    Mecca Madany, Tom M. Thomas, Lincoln Edwards Ph.D. & John S. Yu M.D.

  2. Graduate Program in Biological Science & Translational Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Mecca Madany & Tom M. Thomas

Authors
  1. Mecca Madany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom M. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lincoln Edwards Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John S. Yu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John S. Yu M.D. .

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Moneeb Ehtesham

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Madany, M., Thomas, T.M., Edwards, L., Yu, J.S. (2015). Immunobiology and Immunotherapeutic Targeting of Glioma Stem Cells. In: Ehtesham, M. (eds) Stem Cell Biology in Neoplasms of the Central Nervous System. Advances in Experimental Medicine and Biology, vol 853. Springer, Cham. https://doi.org/10.1007/978-3-319-16537-0_8

Download citation

Publish with us

Policies and ethics

Search

Navigation